A recent study shows that cancer survivors’ out-of-pocket costs for necessary medical equipment are sometimes so high that ...

With half a million people having already received multi-cancer early detection (MCED) screening, patients are and will continue to be asking about these blood tests during their visits, physicians ...

Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of 26,000 patients showed. Overall, 35% of patients' records had evidence of ...

The Epstein-Barr virus is one of the most common and persistent human viruses in the world, according to the CDC.

Cancer survivors who received high-cost immunotherapies appear more likely to experience financial hardship, according to ...

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.  Exact Sciences, which is headquartered in the UW Research Park and has labs along ...

Adam Gray (D-CA), and Neal Dunn (R-FL) introduced the Protecting Patient Access to Cancer and Complex Therapies Act. This legislation would revert physician reimbursement for administering drugs under ...

The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare ...

Dr. Alexandra Zaleta discussed the impact of administrative delays and insurance red tape experienced by patients with ...

An Alabama woman drove to Tampa for answers about her late father’s missing money. Money that she said was siphoned by ...